



## New and Special Subtypes of Breast Cancer

Guest Editors:

### Dr. Katarzyna Pogoda

Breast Cancer and  
Reconstructive Surgery  
Department, Maria Skłodowska-  
Curie National Research Institute  
of Oncology, Warsaw, Poland

### Dr. Elżbieta Senkus

Department of Oncology and  
Radiotherapy, Medical University  
of Gdańsk, Smoluchowskiego 17,  
80-214 Gdańsk, Poland

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editors

In the past two decades, advances in understanding breast cancer (BC) biology have translated into improvements in patients' outcomes. Nowadays, we are witnessing the identification of new biological subtypes of BC, such as the HER2-low subtype. Modern antibody–drug conjugates (ADC) have been created and are tested in that condition; however, we are in the initial stages of the clinical understanding of these special subtypes. The research is also underway to assess the unique characteristics of ER-low BC. Scientific work on specific histological subtypes of breast cancer also brings new insights.

In this Special Issue, “New and Special Subtypes of Breast Cancer”, we invite you to publish papers that focus on the latest achievements in the new BC subtypes including original as well as review articles. Research areas may include (but are not limited to) the following:

- The pathology of new/special BC subtypes;
- The clinical landscape of new/special BC subtypes;
- The challenges in new/special BC subtypes.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)